DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Urelumab is an investigational drug.
There have been 7 clinical trials for Urelumab. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2015.
The most common disease conditions in clinical trials are Lymphoma, Non-Hodgkin, Neoplasms, and Lymphoma, B-Cell. The leading clinical trial sponsors are Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd, and M.D. Anderson Cancer Center.
There are seventeen US patents protecting this investigational drug and two hundred and one international patents.
Recent Clinical Trials for Urelumab
|Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors||Clinica Universidad de Navarra, Universidad de Navarra||Phase 1/Phase 2|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||Bristol-Myers Squibb||Phase 1|
|Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer||University of Chicago||Phase 1|
Top disease conditions for Urelumab
Top clinical trial sponsors for Urelumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Urelumab||Start Trial||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||Start Trial|
|Urelumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Urelumab||Start Trial||Constructs having a SIRP-.alpha. domain or variant thereof||ALX ONCOLOGY INC. (Burlingame, CA)||Start Trial|
|Urelumab||Start Trial||Methods and compositions for treating conditions associated with an abnormal inflammatory responses||First Wave Bio, Inc. (Ann Arbor, MI)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|